What is the current Price Target for the Gemini Therapeutics Inc stock?

The average Gemini Therapeutics Inc target price is $91.80. This is 53.26% higher than the current stock price. The highest price target is 131.39%, the lowest is 43.32%. 13 Analysts have issued a price target Gemini Therapeutics Inc 2026 .

How high will the Gemini Therapeutics Inc stock rise?

No reliable answer can be given as to how high the Gemini Therapeutics Inc stock will rise. The performance of stocks, including the Gemini Therapeutics Inc stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Gemini Therapeutics Inc stock today?

The performance of Gemini Therapeutics Inc stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Gemini Therapeutics Inc stock fall?

The decline in Gemini Therapeutics Inc stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Gemini Therapeutics Inc Forecast, price target & analysts

$59.90

0.13% yesterday

Nasdaq, Sep 15, 10:11 pm CET

ISIN

US36870G1058

Symbol

IRON

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Gemini Therapeutics Inc Target price 2025 - Analyst rating & recommendation

Gemini Therapeutics Inc Classifications & Recommendation:

Buy

94%

Hold

Gemini Therapeutics Inc Price Target

Target Price	$91.80
Price	$59.90
Potential	53.26% register free of charge
Number of Estimates	13

	13 Analysts have issued a price target Gemini Therapeutics Inc 2026 . The average Gemini Therapeutics Inc target price is $91.80. This is 53.26% register free of charge higher than the current stock price. The highest price target is $138.60 131.39% register free of charge , the lowest is $85.85 43.32% register free of charge .
	A rating was issued by 18 analysts: 17 Analysts recommend Gemini Therapeutics Inc to buy, 1 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Gemini Therapeutics Inc stock has an average upside potential 2026 of 53.26% register free of charge . Most analysts recommend the Gemini Therapeutics Inc stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Annually

	Dec '24	2025 Estimates
Earnings Per Share $	-3.96	-5.71
	15.79%	44.19%
P/E		negative

14 Analysts have issued a Gemini Therapeutics Inc forecast for earnings per share. The average Gemini Therapeutics Inc EPS is

Unlock

. This is

Unlock

than earnings per share in the financial year 2024. The highest EPS forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics and future valuations:

2024	$-3.96	15.79%
2025	$-5.71 44.19% Unlock
2026	$-6.26 9.63% Unlock
2027	$-5.21 16.77% Unlock
2028	$-3.50 32.82% Unlock
2029	$-0.41 88.29% Unlock
2030	$4.11 1,102.44% Unlock
2031	$7.72 87.83% Unlock
2032	$11.23 45.47% Unlock

Current	-14.41	1.34%
2025	-10.47 27.36% Unlock
2026	-9.55 8.79% Unlock
2027	-11.49 20.31% Unlock
2028	-17.07 48.56% Unlock
2029	-146.18 756.36% Unlock
2030	14.54 109.95% Unlock
2031	7.75 46.70% Unlock
2032	5.33 31.23% Unlock

Gemini Therapeutics Inc...

Current Gemini Therapeutics Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
Morgan Stanley	Locked ➜ Locked	Locked	Aug 18 2025
Truist Securities	Locked ➜ Locked	Locked	Jul 21 2025
HC Wainwright & Co.	Locked ➜ Locked	Locked	Jul 03 2025
HC Wainwright & Co.	Locked ➜ Locked	Locked	Jun 17 2025
Raymond James	Locked ➜ Locked	Locked	Jun 11 2025
BMO Capital	Locked ➜ Locked	Locked	May 12 2025
Cantor Fitzgerald	Locked ➜ Locked	Locked	Mar 18 2025

Analyst Rating	Date
Locked Morgan Stanley: Locked ➜ Locked	Aug 18 2025
Locked Truist Securities: Locked ➜ Locked	Jul 21 2025
Locked HC Wainwright & Co.: Locked ➜ Locked	Jul 03 2025
Locked HC Wainwright & Co.: Locked ➜ Locked	Jun 17 2025
Locked Raymond James: Locked ➜ Locked	Jun 11 2025
Locked BMO Capital: Locked ➜ Locked	May 12 2025
Locked Cantor Fitzgerald: Locked ➜ Locked	Mar 18 2025

Discover more stocks with a high price target

Novo Nordisk 43.62%

BioNTech SE - ADR 42.25%

Deutsche Telekom 29.89%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now